Laboratory of Clinical Immunology and Microbiology National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Md.
Integrated Data Sciences Section, Research Technology Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Md.
J Allergy Clin Immunol. 2024 Jun;153(6):1655-1667. doi: 10.1016/j.jaci.2023.12.011. Epub 2023 Dec 27.
Functional T-cell responses are essential for virus clearance and long-term protection after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, whereas certain clinical factors, such as older age and immunocompromise, are associated with worse outcome.
We sought to study the breadth and magnitude of T-cell responses in patients with coronavirus disease 2019 (COVID-19) and in individuals with inborn errors of immunity (IEIs) who had received COVID-19 mRNA vaccine.
Using high-throughput sequencing and bioinformatics tools to characterize the T-cell receptor β repertoire signatures in 540 individuals after SARS-CoV-2 infection, 31 IEI recipients of COVID-19 mRNA vaccine, and healthy controls, we quantified HLA class I- and class II-restricted SARS-CoV-2-specific responses and also identified several HLA allele-clonotype motif associations in patients with COVID-19, including a subcohort of anti-type 1 interferon (IFN-1)-positive patients.
Our analysis revealed that elderly patients with COVID-19 with critical disease manifested lower SARS-CoV-2 T-cell clonotype diversity as well as T-cell responses with reduced magnitude, whereas the SARS-CoV-2-specific clonotypes targeted a broad range of HLA class I- and class II-restricted epitopes across the viral proteome. The presence of anti-IFN-I antibodies was associated with certain HLA alleles. Finally, COVID-19 mRNA immunization induced an increase in the breadth of SARS-CoV-2-specific clonotypes in patients with IEIs, including those who had failed to seroconvert.
Elderly individuals have impaired capacity to develop broad and sustained T-cell responses after SARS-CoV-2 infection. Genetic factors may play a role in the production of anti-IFN-1 antibodies. COVID-19 mRNA vaccines are effective in inducing T-cell responses in patients with IEIs.
功能性 T 细胞反应对于清除病毒和在严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)感染后获得长期保护至关重要,而某些临床因素,如年龄较大和免疫功能低下,与较差的结果相关。
我们试图研究 COVID-19 患者和接受 COVID-19 mRNA 疫苗的遗传性免疫缺陷(IEI)个体的 T 细胞反应的广度和幅度。
使用高通量测序和生物信息学工具来描述 540 名 SARS-CoV-2 感染者、31 名接受 COVID-19 mRNA 疫苗的 IEI 受者和健康对照者的 T 细胞受体β库特征,我们量化了 HLA Ⅰ类和Ⅱ类限制的 SARS-CoV-2 特异性反应,并且还鉴定了 COVID-19 患者中的几个 HLA 等位基因-克隆型基序关联,包括亚组抗 I 型干扰素(IFN-1)阳性患者。
我们的分析表明,患有重症 COVID-19 的老年患者表现出较低的 SARS-CoV-2 T 细胞克隆型多样性以及具有较低幅度的 T 细胞反应,而 SARS-CoV-2 特异性克隆型针对病毒蛋白质组中的广泛的 HLA Ⅰ类和Ⅱ类限制表位。抗 IFN-1 抗体的存在与某些 HLA 等位基因相关。最后,COVID-19 mRNA 免疫接种可增加 IEI 患者中 SARS-CoV-2 特异性克隆型的广度,包括那些未能血清转化的患者。
老年人在 SARS-CoV-2 感染后产生广泛和持久的 T 细胞反应的能力受损。遗传因素可能在抗 IFN-1 抗体的产生中起作用。COVID-19 mRNA 疫苗可有效诱导 IEI 患者的 T 细胞反应。